Device Trial Radar · NCT03192696
Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries
Last checked: Nov 19, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Oct 19, 2017
Primary completion
Jun 1, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- Avinger, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 20, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, non-randomized, international, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent Restenotic (ISR) lesions in lower extremity arteries.
Conditions
- Peripheral Arterial Disease
Interventions
Atherectomy CatheterDevice
Treatment of restenotic lesions within stents previously placed within the artery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from a composite of major adverse events (MAEs) through 30-day follow-up (safety)Time frame: Day 0 through 30 days post treatment procedure
- Technical success of Pantheris catheter treatment (efficacy) deviceTime frame: Day 0
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
St. Bernards Medical Center
Jonesboro, Arkansas
Arkansas Heart Hospital
Little Rock, Arkansas
University of California San Diego (UCSD)
San Diego, California
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.